0001493152-22-005242.txt : 20220223 0001493152-22-005242.hdr.sgml : 20220223 20220223163403 ACCESSION NUMBER: 0001493152-22-005242 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220223 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220223 DATE AS OF CHANGE: 20220223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEPHROS INC CENTRAL INDEX KEY: 0001196298 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133971809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32288 FILM NUMBER: 22664349 BUSINESS ADDRESS: STREET 1: 380 LACKAWANNA PLACE CITY: SOUTH ORANGE STATE: NJ ZIP: 07079 BUSINESS PHONE: 201.343.5202 MAIL ADDRESS: STREET 1: 380 LACKAWANNA PLACE CITY: SOUTH ORANGE STATE: NJ ZIP: 07079 8-K 1 form8-k.htm
0001196298 false 0001196298 2022-02-23 2022-02-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 23, 2022

 

NEPHROS, INC.

(Exact name of Registrant as Specified in its Charter)

 

Delaware   001-32288   13-3971809

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

380 Lackawanna Place, South Orange, New Jersey 07079

(Address of principal executive offices, including ZIP code)

 

(201) 343-5202

(Registrant’s telephone number, including area code)

 

n/a

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   NEPH   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On February 23, 2022, Nephros, Inc. (the “Company”) issued a press release in which it disclosed its fourth quarter and fiscal year 2021 financial results. A copy of this press release is furnished herewith as Exhibit 99.1.

 

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Nephros, Inc. Press Release, dated February 23, 2022.

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Nephros, Inc.
       
Dated: February 23, 2022 By: /s/ Andrew Astor
      Andrew Astor
      Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results

 

Reports Full-Year Net Revenue of $10.4 Million, a 22% Year-Over-Year Increase and
Fourth Quarter Net Revenue of $2.8 Million, an 18% Year-Over-Year Increase;
Reaffirms Fiscal Year 2022 Guidance of $13.0 Million to $13.5 Million in Annual Revenue

 

SOUTH ORANGE, NJ, February 23, 2022 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021.

 

Financial Highlights

 

Fourth Quarter Ended December 31, 2021 – Water Filtration Business Segment

 

  ● Net revenue was $2.7 million, compared with $2.3 million in 2020, up 16%
  ● Operating loss was ($0.7 million), compared to ($0.3 million) in 2020
  ● Adjusted Operating Loss was ($64,000), compared with ($10,000) in 2020

 

Fourth Quarter Ended December 31, 2021 – Consolidated

 

  ● Net revenue was $2.8 million, compared with $2.3 million in 2020, up 18%
  ● Net loss was ($1.0 million), compared with ($0.8 million) in 2020, up 37%
  ● Adjusted EBITDA was ($0.4 million), compared with ($0.5 million) in 2020

 

Year-End 2021 – Water Filtration Business Segment

 

  ● Net revenue was $10.2 million, compared with $8.5 million in 2020, up 20%
  ● Operating loss was ($2.9 million), compared with a net loss of ($2.0 million) in 2020
  ● Adjusted Operating Loss was ($1.3 million) in 2021 and 2020

 

Year-end 2021 – Consolidated

 

  ● Net revenue was $10.4 million, compared with $8.6 million in 2020, up 22%
  ● Net loss was ($3.9 million), compared with ($4.5 million) in 2020, down 15%
  ● Adjusted EBITDA was ($2.6 million), compared with ($3.6 million) in 2020

 

“We are pleased to report that Nephros delivered four consecutive quarters of year-over-year growth averaging 19%, ending the year at a new revenue record for the company,” said Andy Astor, President and Chief Executive Officer of Nephros. “Looking forward to 2022, we believe our recent investments into a scalable sales and marketing infrastructure, along with the expected retreat of COVID-19 to endemic state, will bring our growth rates even higher, as evidenced by our recent revenue guidance of $13.0-13.5 million, or 25-30% growth.”

 

1

 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Financial Performance for the Fourth Quarter and Year Ended December 31, 2021

 

Net revenue for the year ended December 31, 2021 was $10.4 million, compared with $8.6 million in 2020, an increase of 22%. Net revenues for the fourth quarter of 2021 were $2.8 million, compared with $2.3 million in the fourth quarter of 2020, an increase of 18%.

 

Cost of goods sold for the year ended December 31, 2021 was $4.7 million, compared with $3.6 million in 2020, an increase of 28%. Cost of goods sold for the fourth quarter of 2021 was $1.3 million, compared with $1 million in the fourth quarter of 2020, an increase of 26%.

 

Gross margins for the year ended December 31, 2021 were 55%, compared with 57% in 2020. Gross margins for the fourth quarter of 2021 were 53%, compared with 56% in the fourth quarter of 2020.

 

Selling, general and administrative expenses for the year ended December 31, 2021 were $7.7 million, compared with $6.5 million in 2020, an increase of 19%. Selling, general and administrative expenses for the fourth quarter of 2021 were approximately $2 million compared with approximately $1.4 million in the fourth quarter of 2020, an increase of 44%.

 

Research and development expenses for the year ended December 31, 2021 were $2.2 million, compared with $2.8 million in 2020, a decrease of 21%. Research and development expenses for the fourth quarter of 2021 were $0.5 million, compared with $0.6 million in the fourth quarter of 2020, a decrease of 19%.

 

Depreciation and amortization expenses for the year ended December 31, 2021 were approximately $202,000, compared with approximately $192,000 in 2020, an increase of 5%. Depreciation and amortization expenses for the fourth quarter of 2021 were approximately $51,000, compared with approximately $50,000 in the fourth quarter of 2020, an increase of 2%.

 

Net loss for the year ended December 31, 2021 was ($3.9 million), compared with a net loss of ($4.5 million) in 2020, a 15% decrease in loss. Net loss for the fourth quarter of 2021 was approximately ($1 million), compared with a net loss of approximately ($0.8 million) in the fourth quarter of 2020, a 37% increase.

 

Adjusted EBITDA for the year ended December 31, 2021 was ($2.6 million), compared with ($3.6 million) in 2020, a 29% decrease. Adjusted EBITDA for the fourth quarter 2021 was approximately ($0.4 million), compared with approximately ($0.5 million) in the fourth quarter of 2020, a 11% decrease.

 

As of December 31, 2021, Nephros had cash and cash equivalents of approximately $7.0 million.

 

2

 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Water Filtration Adjusted Operating Loss Definition and Reconciliation to GAAP Financial Measures

 

Water Filtration Adjusted Operating Loss is calculated by taking operating loss calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all non-recurring expenses and income, and non-cash items, including depreciation and amortization and non-cash compensation. The following table presents a reconciliation of Water Filtration Adjusted Operating Loss to operating loss, the most directly comparable GAAP financial measure for segment reporting, for the 2021 and 2020 fiscal years:

 

Water Filtration

(unaudited)

 

2021  Three Month Period Ended   Annual 
   3/31/2021   6/30/2021   9/30/2021   12/31/2021   Totals 
                     
Operating loss  $(634)  $(875)  $(755)  $(670)  $(2,934)
                          
Adjustments:                         
Depreciation of property and equipment   7    7    7    16    37 
Amortization of other assets   46    48    46    74    214 
Non-cash stock-based compensation   265    269    257    422    1,213 
Other non-cash items   5    24    90    94    213 
                          
Adjusted EBITDA  $(311)  $(527)  $(355)  $(64)  $(1,257)

 

2020  Three Month Period Ended   Annual 
   3/31/2020   6/30/2020   9/30/2020   12/31/2020   Totals 
                     
Operating loss  $(548)  $(852)  $(311)  $(285)  $(1,996)
                          
Adjustments:                         
Depreciation of property and equipment   5    6    7    7    25 
Amortization of other assets   45    45    46    47    183 
Change in FV of contingent consideration   (42)   -    (187)   -    (229)
Non-cash stock-based compensation   190    166    160    200    716 
Other non-cash items   11    12    2    21    46 
                          
Adjusted EBITDA  $(339)  $(623)  $(283)  $(10)  $(1,255)

 

3

 

  

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Consolidated Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures

 

Consolidated Adjusted EBITDA is calculated by taking net loss calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all interest-related expenses and income, non-recurring expenses and income, and non-cash items, including depreciation and amortization and non-cash compensation. The following table presents a reconciliation of Consolidated Adjusted EBITDA to net loss, the most directly comparable GAAP financial measure, for the 2021 and 2020 fiscal years:

 

  

Consolidated

(unaudited)

     
2021  Three Month Period Ended   Annual 
Consolidated  3/31/2021   6/30/2021   9/30/2021   12/31/2021   Totals 
                     
Net loss  $(537)  $(1,126)  $(1,163)  $(1,041)  $(3,867)
                          
Adjustments:                         
Depreciation of property and equipment   7    8    7    16    38 
Amortization of other assets   46    48    46    74    214 
Interest expense   13    11    10    7    41 
Interest income   (3)   (3)   (2)   (2)   (10)
Non-cash stock-based compensation   276    281    268    434    1,259 
Other non-cash items   5    24    90    97    216 
PPP Loan Forgiveness   (482)   -    -    -    (482)
                          
Adjusted EBITDA  $(675)  $(757)  $(744)  $(415)  $(2,591)

 

2020  Three Month Period Ended   Annual 
Consolidated  3/31/2020   6/30/2020   9/30/2020   12/31/2020   Totals 
                     
Net loss  $(1,098)  $(1,657)  $(1,012)  $(759)  $(4,526)
                          
Adjustments:                         
Depreciation of property and equipment   5    6    7    7    25 
Amortization of other assets   45    45    46    47    183 
Interest expense   43    30    22    15    110 
Interest income   (1)   (4)   (3)   (3)   (11)
Change in FV of contingent consideration   (42)   -    (187)   -    (229)
Non-cash stock-based compensation   222    179    172    206    779 
Other non-cash items   11    12    2    21    46 
                          
Adjusted EBITDA  $(815)  $(1,389)  $(953)  $(466)  $(3,623)

 

4

 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Nephros believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to Nephros’s financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros’s consolidated financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA. In order to compensate for these limitations, management presents Adjusted EBITDA in connection with net loss, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA to net loss and not to rely on any single financial measure to evaluate the business.

 

Conference Call Today at 4:30pm Eastern Time

 

Nephros will host a conference call today at 4:30pm ET, during which management will discuss Nephros’s financial results and provide a general business overview.

 

Participants may dial into the following number to access the call: 1 (844) 808-7106. International callers may use 1 (412) 317-5285. Please ask to be joined into the Nephros conference call. A replay of the call can be accessed until March 2, 2022 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 8949087. An audio archive of the call will be available shortly after the call on the Nephros investor relations page at https://investors.nephros.com/events/.

 

About Nephros

 

Nephros, Inc. is a company committed to improving the human relationship with water through leading, accessible technology. We provide innovative filtration and pathogen detection as part of an integrated approach to water safety that combines science, solutions, and support services. Nephros products serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency responses for water management. For more information about Nephros, please visit www.nephros.com.

 

Forward-Looking Statements

 

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’s expected revenue for the quarter and year ended December 31, 2021, expected future revenue growth and the timing of such growth, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including the impact of the ongoing COVID-19 pandemic, uncertainty in clinical outcomes, potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros’s reports filed with the U.S. Securities and Exchange Commission. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

  

Investor Relations Contacts:

 

Kirin Smith, President

PCG Advisory, Inc.

(646) 823-8656

ksmith@pcgadvisory.com

Andy Astor, CEO

Nephros, Inc.

(201) 345-0824

andy.astor@nephros.com

 

5

 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

 

   December 31, 2021   December 31, 2020 
   (unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $6,973   $8,249 
Accounts receivable, net   1,641    1,364 
Inventory   4,795    5,304 
Prepaid expenses and other current assets   225    237 
Total current assets   13,634    15,154 
Property and equipment, net   366    295 
Lease right-of-use assets   730    1,037 
Intangible assets, net   1,536    506 
Goodwill   759    759 
License and supply agreement, net   536    670 
Other assets   89    89 
TOTAL ASSETS  $17,650   $18,510 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Current portion of secured note payable  $248   $229 
Accounts payable   1,334    423 
Accrued expenses   444    341 
Current portion of lease liabilities   364    332 
Total current liabilities   2,390    1,325 
Secured note payable, net of current portion   95    364 
PPP loan   -    482 
Equipment financing, net of current portion   4    7 
Lease liabilities, net of current portion   412    759 
TOTAL LIABILITIES   2,901    2,937 
           
COMMITMENTS AND CONTINGENCIES          
           
STOCKHOLDERS’ EQUITY:          
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020   -    - 
Common stock, $.001 par value; 40,000,000 shares authorized at December 31, 2021 and 2020; 10,258,444 and 9,873,006 shares issued and outstanding at December 31, 2021 and 2020, respectively   10    10 
Additional paid-in capital   147,346    144,296 
Accumulated other comprehensive income   64    74 
Accumulated deficit   (135,725)   (131,858)
Subtotal   11,695    12,522 
Noncontrolling interest   3,054    3,051 
TOTAL STOCKHOLDERS’ EQUITY   14,749    15,573 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $17,650   $18,510 

 

6

 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

 

   Years Ended December 31, 
   2021
(unaudited)		   2020 
Net revenue:          
Product revenues  $10,204   $8,453 
Royalty and other revenues   200    108 
Total net revenues   10,404    8,561 
Cost of goods sold   4,661    3,648 
Gross margin   5,743    4,913 
Operating expenses:          
Selling, general and administrative   7,710    6,466 
Research and development   2,166    2,759 
Depreciation and amortization   202    192 
Change in fair value of contingent consideration   -    (229)
Total operating expenses   10,078    9,188 
Loss from operations   (4,335)   (4,275)
Other income (expense):          
Interest expense   (41)   (110)
Interest income   10    11 
Extinguishment of PPP loan   482    - 
Other income (expense), net   17    (152)
Total other income (expense):   468    (251)
Net loss   (3,867)   (4,526)
Less: Undeclared deemed dividend attributable to noncontrolling interest   (240)   (240)
Net loss attributable to Nephros, Inc. shareholders  $(4,107)  $(4,766)
           
Net loss per common share, basic and diluted  $(0.41)  $(0.52)
Weighted average common shares outstanding, basic and diluted   10,017,830    9,078,549 
           
Comprehensive loss:          
Net loss  $(3,867)  $(4,526)
Other comprehensive (loss) gain, foreign currency translation adjustments   (10)   9 
Comprehensive loss   (3,877)   (4,517)
Comprehensive loss attributable to noncontrolling interest   (240)   (240)
Comprehensive loss attributable to Nephros, Inc. shareholders  $(4,117)  $(4,757)

 

7

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 neph-20220223.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 neph-20220223_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 neph-20220223_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 23, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 23, 2022
Entity File Number 001-32288
Entity Registrant Name NEPHROS, INC.
Entity Central Index Key 0001196298
Entity Tax Identification Number 13-3971809
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 380 Lackawanna Place
Entity Address, City or Town South Orange
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07079
City Area Code (201)
Local Phone Number 343-5202
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol NEPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001196298 2022-02-23 2022-02-23 iso4217:USD shares iso4217:USD shares 0001196298 false 8-K 2022-02-23 NEPHROS, INC. DE 001-32288 13-3971809 380 Lackawanna Place South Orange NJ 07079 (201) 343-5202 false false false false Common stock, $0.001 par value NEPH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nephros.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm neph-20220223.xsd neph-20220223_lab.xml neph-20220223_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "neph-20220223_lab.xml" ] }, "presentationLink": { "local": [ "neph-20220223_pre.xml" ] }, "schema": { "local": [ "neph-20220223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NEPH", "nsuri": "http://nephros.com/20220223", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-02-23to2022-02-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nephros.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-02-23to2022-02-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-005242-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-005242-xbrl.zip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end